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Abstract
Aberrantly expressed G protein-coupled receptors in tumors are considered as potential 
therapeutic targets. We analyzed the expressions of receptors of gonadotropin-
releasing hormone (GNRHR), luteinizing hormone/chorionic gonadotropin (LHCGR) and 
follicle-stimulating hormone (FSHR) in human adrenocortical carcinomas and assessed 
their response to GnRH antagonist therapy. We further studied the effects of the 
GnRH antagonist cetrorelix acetate (CTX) on cultured adrenocortical tumor (ACT) cells 
(mouse Cα1 and Y-1, and human H295R), and in vivo in transgenic mice (SV40 T-antigen 
expression under inhibin α promoter) bearing Lhcgr and Gnrhr in ACT. Both models 
were treated with control (CT), CTX, human chorionic gonadotropin (hCG) or CTX+hCG, 
and their growth and transcriptional changes were analyzed. In situ hybridization and 
qPCR analysis of human adrenocortical carcinomas (n = 11–13) showed expression of 
GNRHR in 54/73%, LHCGR in 77/100% and FSHR in 0%, respectively. CTX treatment in vitro 
decreased cell viability and proliferation, and increased caspase 3/7 activity in all treated 
cells. In vivo, CTX and CTX+hCG (but not hCG alone) decreased ACT weights and serum 
LH and progesterone concentrations. CTX treatment downregulated the tumor markers 
Lhcgr and Gata4. Upregulated genes included Grb10, Rerg, Nfatc and Gnas, all recently 
found to be abundantly expressed in healthy adrenal vs ACT. Our data suggest that CTX 
treatment may improve the therapy of human adrenocortical carcinomas by direct action 
on GNRHR-positive cancer cells inducing apoptosis and/or reducing gonadotropin release, 
directing tumor cells towards a healthy adrenal gene expression profile.
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Introduction
Adrenocortical adenomas can be detected in around 5% of 
the population over the age of 50 (Thompson & Young Jr 
2003), whereas fatal adrenocortical carcinomas are yearly 
diagnosed in 1–2 patients per million (Allolio & Fassnacht 
2006). Adrenocortical carcinomas have a bimodal 
distribution, clustering in children under 10  years and 
adults aged 40–50 years, being 1.5-fold more common in 
women than men (Allolio & Fassnacht 2006). Treatment 
of these cancers mainly involves surgery, adjuvant with 
mitotane and/or chemotherapy, postoperative radiation 
and treatment of the hormone excess (Creemers  et  al. 
2016). These forms of therapy remain inefficient, resulting 
in 5-year survival of only 10–25% (Allolio & Fassnacht 
2006, Fassnacht & Allolio 2009).
Ectopic expression of reproductive hormone G-protein 
coupled receptors (GPCR), such as luteinizing hormone/
chorionic gonadotropin (LHCGR) or gonadotropin-
releasing hormone (GNRHR), has been reported in 
malignancies of reproductive organs (i.e. ovarian, 
breast or prostate) (Huhtaniemi 2010, Ghanghoria  et al. 
2016) as well as in adrenocortical disorders, such as 
adrenocorticortopin-independent adrenal hyperplasia, 
aldosterone-producing ACA and pregnancy-induced 
Cushing syndrome (Carlson 2007, Ziegler  et  al. 2009, 
Huhtaniemi 2010, Albiger  et  al. 2011, Plöckinger  et  al. 
2017). Therefore, treatment with GnRH analogues, to 
block gonadotropin secretion, could provide a therapeutic 
strategy for the above-mentioned tumors (Limonta et al. 
2012, Ghanghoria et al. 2016). GnRH analogues have also 
been shown to act directly on GNRHR expressing cells and 
to promote (splenocytes, thymocytes and lymphocytes) 
or inhibit the growth of normal (ovarian granulosa cells) 
(Park  et  al. 2013) and tumorous (prostate, breast, ovary, 
endometrium, adrenal, lung, pancreatic, melanoma, 
glioblastoma) cells (Ziegler et al. 2009, Jääskeläinen et al. 
2010, Limonta et al. 2012, Park et al. 2013, Seitz et al. 2014). 
Interestingly, even though the signaling mechanisms 
of GnRH agonists and antagonists in pituitary cells 
differ, their direct actions on tumor cells may be similar 
(Limonta  et  al. 2012, Ghanghoria  et  al. 2016). Main 
effects of GnRH analogue treatment on tumor cells are 
the inhibition of proliferation, metastatic potential and 
angiogenesis (Limonta  et  al. 2012, Ghanghoria  et  al. 
2016). Previous in vitro and in vivo xenograft studies 
have had important pitfalls. Firstly, these models did not 
recapitulate the complicated structure of tumor tissue, 
and, secondly, they lacked the fully functional immune 
system. Therefore, more accurate assessment of the 
anti-tumoral efficacy of GnRH analogues in vivo 
necessitates the inclusion of animals naturally developing 
tumors and with intact immune system.
Inhα/Tag mice, expressing Simian Virus 40T antigen 
under the inhibin α promoter, and with an intact immune 
system, are an example of a mouse model developing 
tumors (Kananen et al. 1995, 1996, Chrusciel et al. 2014). 
Intact inhα/Tag mice develop gonadal tumors, but when 
prepubertally gonadectomized, adrenocortical tumors 
appear with a hyperplasia-adenoma-adenocarcinoma 
sequence and abundant LHCGR expression (Kananen et al. 
1995, 1996, Rilianawati  et  al. 1998, Rahman  et  al. 2001, 
2004, Bodek  et  al. 2005, Vuorenoja  et  al. 2007, 2008, 
2009, Chrusciel et al. 2014, Doroszko et al. 2017a,b). The 
formation of gonadal and adrenocortical tumors in these 
mice is gonadotropin dependent, as gonadotropin genetic 
and pharmacological ablation prevented tumor growth 
(Rilianawati et al. 1999). Furthermore, elevated LH levels 
through cross-breeding to LHβ subunit overexpressing 
mice (LHβCT mice) (Risma  et  al. 1995) resulted in 
simultaneous occurrence of gonadal and adrenocortical 
tumors (Mikola et al. 2003). Our recent findings on inhα/
Tag mice showed that, besides LHCGR, the adrenocortical 
tumors express Gnrhr (Doroszko et al. 2017a), and SV40Tag 
expression alone is only able to cause adrenocortical 
hyperplasia but not adenomas (Doroszko et  al. 2017b). 
The transition from hyperplasia to adenoma required LH/
LHCGR signaling, but thereafter tumor progression became 
gonadotropin independent (Doroszko et al. 2017b).
Hereby, we revisited the expression of several GPCRs 
in human adrenocortical carcinomas and mouse adrenal 
tumors and analyzed further the molecular mechanisms 
of the GnRH antagonist action on adrenocortical tumor 
cells in vitro and in vivo.
Materials and methods
Tissue samples
Formalin-fixed paraffin blocks from human adrenocortical 
carcinomas (n = 13) were obtained from the archive of 
the Department of Pathology, Charité Berlin, Germany; 
the clinical information such as age, sex and ENSAT 
score information from the Department of Clinical 
Endocrinology, Charité Berlin, Germany. The study has 
been approved by the Ethics Committee of the Charité 
University Hospital, Germany (No. EA1/169/08), and all 
patients had provided written informed consent. Formalin-
fixed paraffin-embedded tissues were sectioned 5 ± 1 μm 
and stored in the darkness at +4°C for future staining.
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Immunohistochemistry
Localization of proteins was assessed by 
immunohistochemistry. Antigens were retrieved 
using 2100 Antigen Retriever (Aptum Biologics Ltd., 
Southampton, UK) in Tris–EDTA buffer (pH 9, MKI67) or 
citrate buffer (pH6). Samples were washed in TBS with 0.1% 
Tween20 (TBST) (#P1379, Sigma-Aldrich) and blocked 
for 1 h in 3% BSA in TBST at room temperature (RT). 
Antibodies against MKI67 (#MIB-1, Dako, diluted 1:500), 
GNRHR (#19950-1-AP, Proteintech, diluted 1:1000), 
LHCGR (clone 4G2, antibody donated by Dr Marco 
Bonomi); supernatant diluted 1:8 (Bonomi  et  al. 2006) 
or FSHR323 (donated by Dr N. Ghinea) (Vannier  et  al. 
1996) at the concentration of 0.5 µg/mL, were applied on 
the slides and incubated overnight in 4°C. Endogenous 
peroxidase activity was quenched by 10-min incubation 
in 3% hydrogen peroxide (Sigma-Aldrich). Depending 
on the primary antibody host, Dako EnVision+ System-
HRP polymer anti-mouse (K4007, Dako) or anti-rabbit 
(K4011, Dako) were applied, and visualized with Liquid 
DAB + Substrate Chromogen System (Dako). Slides were 
scanned by Pannoramic 250 Slide Scanner (3DHISTECH 
Ltd., Budapest, Hungary) and images were taken using 
Pannoramic Viewer (3DHISTECH Ltd.). The percentage of 
MKI67-stained cells was assessed using ImmunoRatio web 
application (http://153.1.200.58:8080/immunoratio/) 
(Tuominen  et  al. 2010) from four representative images 
of each sample.
In situ hybridization
In situ hybridization (ISH) was performed using RNAscope 
2.5 HD Reagent Kit-BROWN (Advanced Cell Diagnostics, 
Newark, CA, USA) (Wang  et  al. 2012) with predesigned 
probes for GNRHR (#407999), LHCGR (#300031), FSHR 
(#408101), positive control POLR2A (#310451) and 
nonsense dapB (from Bacillus S., #310043). Hybridization 
was performed according to manufacturer’s protocol in 
HybEZ Oven (Advanced Cell Diagnostics). Slides were 
scanned by Pannoramic Midi FL slide scanner (3DHISTECH 
Ltd.) and pictures were taken using Pannoramic Viewer 
(3DHISTECH Ltd.).
In vitro
Cell culture
Cα1 (Kananen et al. 1996) cell line was established from 
a founder female adrenocortical tumor of C57Bl/6 strain 
genetic background mouse. Y-1 (ATCC) was derived from 
a minimally deviated tumor that arose in an adult LAF1 
(C57L × A/HeJ) male mouse, following an exposure of the 
mouse to the radiation of an atomic blast (Cohen  et al. 
1957). Human H295R (ATCC) cell line was isolated from 
a female adrenocortical carcinoma patient (Rainey  et al. 
1994). These cell lines used in our study were mycoplasma-
free. DMEM/F12 (#D2906, Sigma-Aldrich) culture media 
containing 5 U/mL of penicilin/streptomycin (#15140-122, 
Fisher Scientific) were supplemented for each cell line as 
follows, Cα1 10% fetal bovine serum (FBS); Y-1 15% fetal 
horse serum (FHS) and 2.5% FCS; H295R 2.5% NuSerum 
(#355100, Corning, New York, NY, USA) and 1× Corning 
ITS Premix Universal Culture Supplement (#354352, 
Corning).
Cetrorelix acetate (#C5249, Sigma-Aldrich) was 
dissolved in 0.1% DMSO (#D8418, Sigma-Aldrich). 
Recombinant hCG was kindly donated by Organon 
(Oss, Netherlands). Concentrations of cetrorelix 
acetate and hCG were validated and set for 10 µM and 
10 ng/mL respectively. For all experiments, Y-1 and H295R 
cells were seeded and stimulated in full culture media, 
whereas Cα1 cells in medium containing 2.5% FBS. After 
attaching overnight medium was changed to the medium 
containing 0.1% DMSO as control (CT), 10 µM CTX 
(CTX), 10 µM CTX and 10 ng/mL of hCG (CTX + hCG) or 
10 ng/mL of hCG (hCG) solutions.
Viability test
Viability of the cells was checked using MTS CellTiter 
96 Aqueous Non-Radioactive Cell Proliferation Assay 
(Promega). In brief, cells were seeded on 24-well plates 
(Cα1 = 120,000 cells/well, Y-1 = 180,000 cells/well, H295R = 
180,000 cells/well) and after 48 h of treatment medium 
was changed for DMEM/F12 medium containing MTS 
reagent. Cells were incubated for 240 min in 37°C and 
absorbance at 495 nm was read using Wallac 1420 Victor2 
Microplate Reader (Perkin Elmer).
Proliferation test
Cells were seeded on 96-well plate (Cα1 = 4000 
cells/well, Y-1 = 8000 cells/well, H295R = 8000 cells/well) 
and after 48 h of treatment medium was decanted and 
plates frozen in −80°C overnight. After thawing, CyQUANT 
Cell Proliferation Assay Kit (#C7026, Life Technologies) 
was applied and DNA standard curves for each cell line 
were prepared according to manufacturer’s instructions. 
Fluorescence was read at Ex/Em = 480 nm/520 nm with 
Wallac 1420 Victor2 Microplate Reader (Perkin Elmer). 
Results were recalculated using determination based 
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on a DNA standard curve, normalized to the control 
group for every cell line and presented as a percent 
of stimulation.
Apoptosis assay
Activity of Caspase 3/7 was assessed using Caspase Glo 3/7 
kit (Promega) according to the provided protocol. In brief, 
cells were seeded 8000/well on a 96-well plate, attached 
overnight and treated with CT (0.1% DMSO as control) 
or 10 µM CTX (CTX) for 6h. Absolute luminescence was 
normalized by CT-treated values.
GNRHR knockdown studies
To knockdown GNRHR in H295R cells, we delivered 
anti-GNRHR ON-TARGETplus SMARTpool (#L-005517-
00-0005, Dharmacon) libraries using Lipofectamine 
RNAiMAX Transfection Reagent (Fisher Scientific). 
As a negative and positive control ON-TARGETplus 
Non-targeting Pool (#D-001810-10-05) and AllStars 
Hs Cell Death Control siRNA (#SI04381048, Qiagen) 
were used, respectively. Reverse transfection according 
to manufacturer’s protocol, in triplicates with a final 
50 pmol siRNA concentration was performed and after 
overnight incubation medium was changed into full 
culture medium. After 72 h, each of the cell replicates 
were detached and seeded either onto 96-well plates for 
proliferation (n = 6/replicate) and caspase 3/7 activity 
studies (n = 3/replicate) or harvested for Western blot 
analysis (n = 1/replicate).
Western blot
Cells were rinsed with cold PBS and scraped on ice 
with RIPA buffer (Fisher Scientific) with addition of 
protease and phosphatase inhibitors (cOmplete ULTRA 
Tablets and PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets, Roche). Equal amounts of total protein (20 μg) 
were separated on 10% polyacrylamide gels for 1.5 h 
at 100 V in 4°C. Proteins were transferred onto PVDF 
membranes using a semi-dry transfer for 30 min at 
20 V. Membranes were blocked in 5% non-fat milk 
and incubated overnight with anti-GNRHR primary 
antibody (1:500; GNRHR03, MA5-11538, Invitrogen) at 
4°C. Next day, membranes were washed in TBST and 
anti-mouse HRP-linked secondary antibody (Abcam) 
was applied for 30 min at RT. Amersham Biosciences 
ECL detection system (GE Healthcare, Little Chalfont, 
UK) was used for signal visualization. Images were 
taken using ChemiDoc MP imager (Bio-Rad). After 
visualization membranes were stripped using ReBlot Ta
b
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Plus Strong Antibody Stripping Solution (Sigma-
Aldrich), blocked in 5% non-fat dry milk and incubated 
overnight (4°C with gentle agitation) with primary 
anti-actin beta (ACTB) antibody (1:1000; A2228, Sigma-
Aldrich). Intensity of the signals was calculated using 
ImageJ (NIH) software based on the measurements of 
three membranes.
In vivo
In this study, we used inhα/Tag (transgenic mice 
expressing SV40 Tag oncogene under the inhibin 
α promoter) (Kananen et al. 1995, 1996) males and females 
(n = 6–8/gender/group). To induce adrenocortical tumors, 
animals were prepubertally (in between 21 and 24 days of 
Figure 1
Localization of gonadotropin receptors in human and mouse adrenocortical tumors/cancer. Representative images of hematoxylin and eosin, immuno-
localization of MKI67, in situ RNA/protein localization of GNRHR, LHCGR and FSHR in human adrenocortical carcinoma sections from Patient 11 (panel A) or 
adrenocortical tumor sections of inhα/Tag mouse (panel B). Bar = 50 µm. 
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their lives) gonadectomized under Isoflurane anesthesia 
(Isoflo, Orion, Finland). Temgesic (buprenorphine, 
0.1 mg/kg/8 h) (Schering-Plough, Brussels, Belgium) and 
Comforion (ketoprofen, 5 mg/kg/24 h) were administered 
subcutaneously as a post-operative analgesia. Mice were 
raised in a pathogen-free media surrounded with controlled 
light (12 h light: 12 h darkness) and temperature (21 ± 1°C). 
Mice were housed two to five per cage, fed with mouse 
chow SDS RM-3 (Whitham, Essex, UK) and tap water ad 
libitum. Ethics Committees for animal experimentation 
of the Turku University and the State Provincial Office of 
Southern Finland approved all the animal experiments 
(ESAVI/3324/04.10.07/2014).
Preparation of drugs and treatments
Cetrorelix acetate (CTX, Sigma-Aldrich) was dissolved in 
sterile water and 0.75 mg/mL stock solution, kept in +4°C 
and used out within 6 days after reconstitution. Pregnyl 
5000 IU (Merck) was dissolved in 99 mL of Natriumchlorid 
B. Braun 9 mg/mL (#630966, Braun, Melsungen, 
Germany), aliquoted into 1 mL syringes and frozen in 
−20°C. Single dose of cetrorelix acetate was 3 mg/kg/48 h, 
whereas Pregnyl 5 IU/30 g/week. At the age of 6.5 months, 
GDX inhα/Tag mice were randomly divided into 
experimental groups (n = 6–8/group/gender) and injected 
intraperitoneally for 21  days with weight-dependent 
amount of substance (1): saline as control (CT; Natrium 
chloride B. Braun 9 mg/mL (Braun)) (2), CTX (3), CTX 
together with Pregnyl (CTX + hCG) or (4) Pregnyl only 
(hCG). On day 23, mice were killed by exsanguination 
under isoflurane anesthesia. Blood was collected into a 
tube consisting 0.5 M sterile EDTA solution, and plasma 
was separated by centrifugation at 1800 g for 10 min in 
4°C, and stored in −80°C for hormone measurements. 
After taking the weights, tissues were snap-frozen in liquid 
nitrogen or fixed with 4% paraformaldehyde.
RNA isolation and gene expression analysis
Total RNA from mouse adrenal tumors (n = 5/group/sex), 3 
passages of cell lines (Cα1, Y-1, H295R), 11 adrenocortical 
carcinomas, 2 healthy adrenal glands or Cα1 and Y-1 cells 
treated for 24 h with control (CT; 0.1% DMSO as control) 
and CTX was extracted using TRIsure reagent (Bioline 
Reagents Ltd., London, UK) according to manufacturer’s 
protocol. RNA was quantified with Nanodrop (Fisher 
Scientific) and qualified by gel electrophoresis. Nine 
hundred nanograms of total RNA were treated with 
Amplification Grade DNase I (#AMPD1-1KT, Sigma-
Aldrich) and transcribed (1 h in 48°C) using SensiFAST 
cDNA Synthesis Kit (#BIO-65053, Bioline Reagents 
Ltd.). qPCR reaction was consisting Fast SYBR Green 
Master Mix (Fisher Scientific), 7.5 ng of DNA template 
and primers from Supplementary Table  1(see section 
on supplementary data given at the end of this article). 
qPCR was run on CFX Real Time PCR Detection System 
(Bio-Rad) in total reaction volume of 10 µL in duplicates. 
Cycling conditions were as follows: 95°C for 30 s, (95°C 
for 10 s, 60–62°C for 30 s) ×40, 72°C for 2 min, 65–95°C 
melt curve. Reference genes were validated for specific 
tumor type and cell line using Bio-Rad CFX Manager 
Software (Bio-Rad). Gene expression was normalized by 
at least 2 reference genes using qBase MSExcel VBA applet 
(Hellemans et al. 2007).
In silico
To study global gene expression changes affected by CTX 
treatment, we compared adrenals of GDX inhα/Tag mice 
after 21-day treatment with CTX or CT (n = 4/group).
Figure 2
mRNA levels of GNRHR/Gnrhr and LHCGR/Lhcgr in normal and adrenal 
tumor/cancer tissues and cell lines. Expression of GNRHR (A) and LHCGR (B) 
in normal human adrenals (ADR) (n = 3), adrenocortical carcinomas (ACC) 
(n = 11) and H295R cell line (n = 3). Expression of Gnrhr (C) and Lhcgr (D) in 
normal mouse ADR (n = 5), ACT (n = 5) and cell lines Cα1 and Y-1. ACC, 
adrenocortical cancer, ACT, adrenocortical tumor; ADR, normal adrenal. 
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Total RNA was extracted using RNeasy Mini Kit (Qiagen) 
according to manufacturer’s protocol and qualified using 
Bioanalyzer nano kit (Agilent Technologies). cDNA was 
synthetized using the MessageAmp II aRNA Amplification 
Kit (Applied Biosystems) and ran on Agilent whole mouse 
genome oligo microarrays 4X44K (#GPL7202, Agilent 
Technologies, Santa Clara, CA, USA) accordingly to 
manufacturer’s protocol. Quantile normalization with 
Iimma R/Bioconductor package and a row-wise t-test 
were performed. Genes with fold-change higher than 2 
and P-value lower than 0.05 were considered significant. 
Targets with P-value <0.1 and fold-change <1.2 for males 
and females were compared in Venn diagram (http://
bioinfogp.cnb.csic.es/tools/venny/). List of treatment 
affected targets was uploaded to the PANTHER classification 
system (Mi et al. 2013) and statistical overrepresentation 
test was performed. Genes were classified using PANTHER 
GO-Slim Biological Processes and PANTHER pathways 
annotation data sets.
Statistical analysis
To detect statistical differences between two or more 
experimental groups, we used Mann–Whitney U test 
or Kruskal–Wallis test with multiple comparison of 
mean range as post hoc analysis respectively. Numerical 
data were presented as mean ± s.e.m. Statistical analysis 
and graphs were prepared using Graph Pad Prism 6 
(GraphPad Software), and P < 0.05 values were considered 
as significant.
Figure 3
Cell viability, proliferation and caspase 3/7 activity 
in vitro. Viability (A) and proliferation (B) of Cα1, 
Y-1 and H295R cells after 48 h treatment with CT, 
CTX, CTX and hCG or hCG alone. Caspase 3/7 
activity (C) in Cα1, Y-1 and H295R cells assessed 
after culture with CTX for 6 h (mean ± s.e.m.; 
*P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001). CT, 0.1% 
DMSO as control; CTX, cetrorelix acetate; hCG, 
human chorionic gonadotropin. 
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Results
Expression of GNRHR, LHCGR and FSHR in 
adrenocortical tumors and cell lines
We determined the mRNA and protein expression 
of GNRHR, LHCGR and FSHR genes in samples from 
13 patients, 6 males and 7 female patients, 30–72 years 
of age, presenting with diverse hormone excess 
manifestations (Table  1). Adrenocortical carcinoma 
samples were classified according to the European 
Network for the Study of Adrenal Tumors (ENSAT) 
scale from 2 to 4, and MKI67 proliferation index 
spanning between 2 and 50% (Table  1). In order to 
assess whether the adrenocortical carcinoma samples 
express GNRHR, LHCGR and FSH expression was studied 
using a commercial in situ hybridization RNAscope kit 
with single transcript resolution (Wang et  al. 2012). We 
detected GNRHR in 54%, LHCGR in 77% and FSHR in 
0% of the cancer samples (Table  1). The representative 
images of hematoxylin and eosin, immunohistochemical 
staining of MKI67, and localization of GNRHR/GNRHR, 
LHCGR/LHCGR and FSHR/FSHR transcripts and proteins 
in the human adrenocortical malignancies and in 
inhα/Tag adrenals are presented in the left (Fig.  1A) 
and right (Fig.  1B) panel, respectively. qPCR confirmed 
the expression of GNRHR/Gnrhr (Fig.  2A and C) and 
LHCGR/Lhcgr (Fig. 2B and D) in the normal human and 
mouse adrenals, adrenocortical tumors and H295R, Cα1, 
Y-1 cell lines (except Lhcgr in Y-1).
CTX decreased cell viability and proliferation in vitro 
and tumor size in vivo
To evaluate the potential tumor-regressing effect of CTX, 
we treated adrenocortical tumor cells in vitro and in vivo. 
To discriminate between direct and indirect CTX effects, 
we maintained LHCGR stimulation with hCG treatment. 
CTX alone or in combination with hCG (CTX + hCG) 
decreased the viability (Fig.  3A) and proliferation 
(Fig. 3B) of Cα1, Y-1 and H295R cells, whereas hCG alone 
significantly increased the viability and proliferation of 
H295R cells only (Fig. 3A and B). Moreover, CTX treatment 
increased the activity of caspase 3/7 in all treated cell lines 
(Fig. 3C). In vivo CTX and CTX + hCG treatments decreased 
adrenocortical tumor size of male (Fig.  4A) and female 
(Fig. 4B) mice as well as decreased LH (Fig. 4C and D) and 
progesterone (Fig. 4E and F) plasma concentrations when 
compared to CT. hCG treatment alone had no impact 
on the tumor size or plasma hormone concentrations 
(Fig. 4C, D, E and F).
CTX acts through GNRHR expressed in tumor cells
To confirm that the effect of CTX on adrenocortical 
carcinoma cells acts through GNRHR, we performed 
siRNA-mediated GNRHR knockdown in human H295R 
cells. Western blot analysis (Fig.  5A) revealed 78% 
Figure 4
CTX treatment efficacy in vivo. Adrenal tumor weights (A and B) and 
plasma LH (C and D) and progesterone (E and F) concentrations of mice 
treated for 21 days with saline as control (CT), CTX, CTX and hCG, or hCG. 
(n = 6–8/group; mean ± s.e.m.; *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001). CT, 
saline; CTX, cetrorelix acetate; hCG, human chorionic gonadotropin. 
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knockdown of GNRHR protein levels (siGNRHR), 
as compared to cells transfected with non-targeting 
siRNA libraries (siControl) (Fig.  5B). Basal proliferation 
between siGNRHR and siControl cells was similar, and 
after 48-h CTX treatment, the proliferation of both was 
decreased (Fig. 5C). However, the inhibition of siGNRHR 
cell proliferation was significantly greater than that of 
siControl cells (Fig. 5C). Caspase 3/7 activity was similar 
in siGNRHR and siControl, but after CTX treatment 
significantly increased only in siControl cells (Fig. 5D).
Global gene expression changes of adrenocortical 
tumors in inhα/Tag mice
cDNA microarray analyses were run to identify the 
potential biological processes and pathways affected by 
CTX in ACTs of inhα/Tag mice. Due to high individual 
variation of tumor sizes, we considered fold change 
of ±1.2 and P value <0.1 significant. Complete cDNA 
microarray data can be found through ArrayExpress 
(accession number E-MTAB-5310). In females, CT 
vs CTX, 1714 genes were differently expressed, 918 
upregulated and 796 downregulated. In males, CT 
vs CTX, 4390 genes were altered, 2506 up- and 1884 
downregulated (Fig.  6A). As the individual variation of 
tumor size was lower in males than in females, we used 
the male dataset for further processing. Enrichment 
analysis with PANTHER classification system was used 
to cluster genes into biological processes and pathways. 
The most interesting processes (marked with arrowheads) 
were growth, biological adhesion, immune system, 
development and response to stimulus (Fig. 6B). Among 
dysregulated pathways, the most conspicuous (marked 
with arrowheads) were p53, apoptosis signaling, EGF 
receptor signaling, FGF signaling, gonadotropin-releasing 
hormone receptor, G-protein signaling pathways, 
angiogenesis, inflammation mediated by chemokine and 
cytokine signaling and Wnt signaling pathways.
Gene expression signatures of CTX treatment in 
adrenocortical tumors of inhα/Tag mice
Previously, we reported an array of genes up- or 
downregulated in adrenocortical tumors of inhα/Tag mice, 
when compared to WT littermates (Doroszko et al. 2017a). 
Interestingly, a subset of the genes such as transcription 
factor GATA4 (Gata4), Lhcgr, sarcoglycan delta (Sgcd), 
Figure 5
GNRHR knockdown in H295R adrenocortical 
carcinoma cells. Western blot analysis of GNRHR 
expression in WT (H295R), transfected with 
non-targeting (siControl) or GNRHR-targeting 
(siGNRHR) siRNA H295R adrenocortical carcinoma 
cells (A). Densitometric analysis of the GNRHR 
protein levels in H295R, siControl and siGNRHR 
cells (n = 3) (B). The effect of CTX treatment on 
proliferation (n = 12) (C) and caspase 3/7 
activation (n = 9) (D) in siControl and siGNRHR 
cells (mean ± s.e.m.; *P ≤ 0.05. **P ≤ 0.01. 
***P ≤ 0.001). 
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matrix metallopeptidase 24 (Mmp24), growth factor 
receptor-bound protein 10 (Grb10), RAS-like estrogen-
regulated growth inhibitor (Rerg), gonadotropin-releasing 
hormone receptor (Gnrhr), G-protein-coupled receptor 
nuclear factor of activated T cells, calcineurin-dependent 
2 (Nfatc2) and guanine nucleotide-binding protein alpha-
stimulating complex locus (Gnas) also appeared in this 
microarray analysis. qPCR validation of the microarray 
analysis in murine adrenocortical tumors treated with CTX 
vs CT showed downregulation of Gata4 (Fig.  7A), Lhcgr 
(Fig.  7B), Cyclin A1 (Ccna1) (Fig.  7C) and upregulation 
of extracellular matrix compounds such as Sgcd (Fig. 7D), 
Mmp24 (Fig. 7E); genes related to cell growth suppression, 
Grb10 (Fig.  7F), Rerg (Fig.  7G); G0/G1 Switch 2 (G0s2) 
(Fig. 7H); Tumor Suppressor Candidate 5 (Tusc5) (Fig. 7I) or 
GPCR-mediated Ras protein-specific guanine nucleotide-
releasing factor 1 (Rasgrf2) (Fig. 7J). In addition, we found 
upregulation of Gnrhr (Fig.  7K) and the downstream 
mediators of G-protein-coupled receptor Nfatc2 (Fig.  7L) 
and Gnas (Fig. 7M). Interestingly, none of these genes were 
altered in CTX-treated cells in vitro (Fig. 7A, B, C, D, E, F, G, 
H, I, J, K, L and M).
Discussion
In recent years, several studies have detected the 
expression and function of the two reproductive hormone 
receptors, GNRHR and LHCGR, in non-gonadal tissues 
and malignancies (Alevizaki et al. 2006, Bernichtein et al. 
2008, Lacroix  et  al. 2010, Banerjee & Fazleabas 2011, 
Limonta  et  al. 2012). In adrenal glands, gonadotropins, 
especially LH, may exert hormonal and hyperplastic effect 
(Carlson 2007, Plöckinger  et  al. 2017) as well as induce 
various adrenocortical pathologies. GNRHR expression 
has also been found in adrenocortical adenomas 
producing aldosterone (Albiger  et  al. 2011). Previously, 
Figure 6
Gene ontology (GO) classification based on 
biological processes and pathways affected by 
CTX treatment in vivo. Venn diagram of 
upregulated and downregulated genes in the 
adrenal glands of male and female mice treated 
with CTX (cetrorelix acetate) or CT (saline as 
control) for 21 days (A). Significantly upregulated 
or downregulated genes were classified based on 
the biological processes (B) and pathways (C) they 
are involved in. The analysis shows the number of 
dysregulated genes in the adrenocortical tumors 
of inhα/Tag treated with CT vs CTX. 
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GNRHR localization was shown in normal adrenal 
glands (medulla and cortex), adrenocortical adenomas 
and in the SW13 adrenocortical cell line, but never in 
adrenocortical carcinomas (Ziegler  et  al. 2009). LHCGR 
expression has been demonstrated in normal human 
adrenals (Pabon et al. 1996) and in various adrenocortical 
malignancies (Carlson 2007). FSHR has been found only 
by immunohistochemical localization in the intra- and 
peri-tumoral vessels of adrenal tumors (Pawlikowski et al. 
2012). Reliable localization of gonadotropin receptors is 
challenging due to a lack of good-quality commercially 
available antibodies. Therefore, in our studies, we analyzed 
Figure 7
qPCR validation of selected genes from microarray study in inhα/Tag adrenal tumors and cell lines (Cα1 and Y-1) treated with CTX vs CT. Gene expression 
of Gata4 (A), Lhcgr (B), Ccna1 (C), Sgcd (D), Mmp24 (E), Grb10 (F), Rerg (G), G0s2 (H), Tusc5 (I), Rasgrf1 (J), Gnrhr (K), Nfatc2 (L), Gnas (M) in inhα/Tag adrenal 
tumors and Cα1 and Y-1 cell lines treated with CTX (cetrorelix acetate) vs CT (0.1% DMSO as control). (n = 3–5/group; mean ± s.e.m.; *P ≤ 0.05. **P ≤ 0.01. 
***P ≤ 0.001). 
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their expression levels by qPCR, mRNA localization in 
the tissue sections by a commercial in situ hybridization 
RNAscope kit and protein localization using in-house 
antibodies. We found that human adrenocortical 
carcinomas and mouse adrenocortical tumors expressed 
GNRHR and LHCGR mRNA and protein at variable levels, 
probably due to the well-known high heterogeneity of 
the tumors (Allolio & Fassnacht 2006). However, we were 
unable to detect FSHR transcripts or protein, in contrast 
to an earlier report (Pawlikowski  et  al. 2012), which 
used only immunohistochemistry. The inconsistency 
between RNA levels and protein detection using poorly 
characterized antibodies against FSHR is well recognized, 
necessitating RNA and protein measurements in tandem 
to ensure specificity and sensitivity of the FSHR detection 
(Stelmaszewska et al. 2016).
The present in vivo and in vitro data unequivocally 
showed that CTX could act directly on tumors causing 
their regression. CTX treatment decreased cell viability 
and proliferation as well as increased apoptosis in mouse 
and human adrenocortical tumors and cancer cell lines. 
GNRHR knockdown to reduce CTX action ultimately 
confirmed the on-target CTX effect. Similar direct GnRH 
antagonist effects on proliferation and cell death have 
been reported in prostate (Sakai  et  al. 2015), breast, 
uterine, lung (Ghanghoria et al. 2016) and adrenocortical 
(Ziegler  et al. 2009) cell lines. Previous CTX treatment of 
adrenocortical tumors in inhα/Tag mice (Vuorenoja  et al. 
2009) showed tumor regression, which was attributed 
to systemic effect through inhibition of LH release. 
In contrast, we found now that hCG treatment did not 
affect Cα1 cell proliferation or tumor growth in vivo, 
which supports our recent report that adrenocortical 
tumor progression in inhα/Tag mice may be gonadotropin 
independent (Doroszko  et  al. 2017b). Additionally, the 
systemic action of CTX treatment in vivo was manifested 
by reduced plasma concentrations of LH and progesterone 
levels. Combining hCG with CTX treatment did not affect 
the outcome, implying that the CTX effect was independent 
of gonadotropin suppression but rather a direct effect on the 
adrenal tumors. Previously, H295R cells have been shown 
to express LHCGR and respond to hCG stimulation by 
producing DHEAS (Rao et al. 2004). In the current study, we 
confirmed the LHCGR expression in H295R adrenocortical 
carcinoma cells and showed that hCG stimulation resulted 
in mitotic effect. These data suggest a scenario of combined 
CTX action by direct blockage of adrenocortical tumor 
progression and indirect suppression of LH and steroid 
hormone concentrations that could be used for the benefit 
of the patient.
Gonadectomized domestic ferrets are another model 
that develops malignant adrenocortical tumors with 
gonadal-like phenotype (Li et al. 1998). Similar to inhα/Tag 
mice, tumor onset in ferrets was attributed to LH action. 
Therefore, therapies with GnRH agonist (Wagner  et  al. 
2001, 2005) or GnRH adjuvant (Miller et al. 2013) to block 
circulating gonadotropins and subsequent hormone 
excess have been effective. It would be interesting to 
validate the LH dependency of the tumor progression 
and the expression of GNRHR in the ferret adrenal 
tumor tissues, as they could serve as another model for 
adrenocortical carcinomas.
Although the anti-angiogenic, anti-metastatic and 
pro-apoptotic effects of GnRH antagonists are well 
documented (Ghanghoria  et  al. 2016), the molecular 
mechanisms of their action remains poorly understood. A 
study on prostate cancer cell lines, with a different GnRH 
antagonist, degarelix, showed rather discrete mRNA 
changes after in vitro treatment (Sakai et al. 2015). It was 
suggested that the initial effects of GnRH antagonist 
could be non-genomic, directly triggering apoptosis 
in the effector cells (Sakai  et  al. 2015). To investigate 
the molecular changes in tumor cells induced by CTX, 
we carried out microarray analyses supported by qPCR 
validation. Arrays of genes were found upregulated, such 
as (Mmp24, Rerg, Grb10, Gnrhr, Gnas, Nfatc2 and Sgcd) and 
downregulated, such as (Gata4 and Lhcgr), in agreement 
with a previous study where tumorous and WT adrenals 
were compared (Doroszko  et  al. 2017a). Moreover, we 
have identified downregulation of Ccna1, an important 
contributor to G1/S cell cycle transition in somatic cells 
(Ji  et  al. 2005) and upregulation of genes related to cell 
growth suppression, such as G0s2 (Welch et al. 2009) and 
Tusc5 (Konishi  et  al. 2003), Rasgrf2 (Qiu  et  al. 2003) in 
the CTX vs CT-treated adrenals. Interestingly, none of the 
investigated genes was affected in the Cα1 and Y-1 cell 
lines treated with CTX. This suggests that the regulation 
of gene expression does not proceed in the same fashion 
when tumor cells are grown in vitro. Downregulation 
of the tumor biomarkers Gata4 and Lhcgr could be a 
sign of regressing tumor cells. On the other hand, the 
upregulated Grb10, Rerg, Gnas and Nfatc2, recently 
localized in abundance in the healthy adrenal gland 
(Doroszko et al. 2017a), could be a sign of physiological 
and regenerative response to replenish healthy adrenal. 
Therefore, our findings support the idea that the GnRH 
antagonist functions as a safe antitumor treatment that 
selectively and directly kills adrenocortical tumor cells.
Taken together, our data suggest that the GnRH 
antagonist cetrorelix acetate acts directly on adrenocortical 
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tumor cells causing their apoptosis. The compound could 
improve the therapy of both hormone-secreting and 
non-secreting adrenocortical carcinomas both through 
systemic and direct action.
Supplementary data
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